- Author edit:
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, GT Healthcare Capital and funds managed by Blackrock. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.
Read more ›